Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 14(23): 8109-25, 2006 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-16893650

RESUMO

HIV-1 infection of the brain and PAF neurotoxicity are implicated in AIDS dementia complex. We previously reported that a trisubstituted piperazine derivative is able to diminish both HIV-1 replication in monocyte-derived macrophages and PAF-induced platelet aggregation. We report in this work new compounds obtained by modifying its piperazine substituents. The structure-activity relationship study shows that a better dual activity or even pure antiretroviral compounds can be obtained in this series.


Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Fármacos Anti-HIV/síntese química , Antirretrovirais/síntese química , Demência/prevenção & controle , Piperazinas/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Fármacos Anti-HIV/farmacologia , Antirretrovirais/farmacologia , Demência/etiologia , Relação Dose-Resposta a Droga , HIV-1 , Humanos , Piperazinas/síntese química , Relação Estrutura-Atividade
2.
J Med Chem ; 47(25): 6410-9, 2004 Dec 02.
Artigo em Inglês | MEDLINE | ID: mdl-15566310

RESUMO

The HIV-1 central nervous system infection leads to the onset of neurological impairments called AIDS dementia complex (ADC). PAF plays an important role in this pathology, as it is an HIV-1-induced neurotoxin produced by infected or activated macrophages and microglia, in the brain. We previously reported that PAF-antagonists bearing a trisubstituted piperazine presented in vitro anti-HIV-1 activity in human macrophages. To improve the pharmacological activities of our lead compound, 1a, we modified its carbamate function and evaluated both its antiretroviral and anti-PAF activities. One carbamate derivative (10c) demonstrated a similar antiviral activity but a higher anti-PAF potency, whereas 4a, with an ureide function, presents an increased antiviral activity and can be considered as a pure antiretroviral drug, as it does not present PAF-antagonism. Moreover, we measured the ability of 1a to cross the blood-brain barrier, using the in situ mouse brain perfusion method and its plasmatic concentrations after iv and po administration. The transport parameter measured (K(in)) proves that 1a is able to cross this biological barrier, but a pharmacokinetic study reveals its weak bioavailability in rats.


Assuntos
Fármacos Anti-HIV/síntese química , HIV-1/efeitos dos fármacos , Piperazinas/síntese química , Fator de Ativação de Plaquetas/antagonistas & inibidores , Animais , Fármacos Anti-HIV/química , Fármacos Anti-HIV/farmacologia , Disponibilidade Biológica , Barreira Hematoencefálica/metabolismo , Carbamatos/síntese química , Carbamatos/química , Carbamatos/farmacologia , Células Cultivadas , Humanos , Técnicas In Vitro , Macrófagos/efeitos dos fármacos , Macrófagos/virologia , Masculino , Camundongos , Permeabilidade , Piperazinas/química , Piperazinas/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Coelhos , Ratos , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Replicação Viral/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...